DEImedi s.r.o.

Research site

Slovakia Mudrochova 966/2, 942 01 Šurany, Slovakia

1 trial recruiting
Type 2 diabetes mellitus · Obesity · Overweight
Adult patients

About Specializations

DEImedi s.r.o. in Šurany, Slovakia specialises in clinical trials of conditions such as Type 2 diabetes mellitus, Obesity, Overweight, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Mudrochova 966/2942 01 ŠuranySlovakia

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 3

More sites in Šurany Slovakia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

2 clinical trials

Type 2 diabetes mellitus+2

Recruiting

A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

Investigational

A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

Investigational

Slovakia

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Type 2 diabetes mellitus

Not yet recruiting

Efficacy and safety of weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes not controlled by diet and exercise

Investigational

Efficacy and safety of weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes not controlled by diet and exercise

Investigational

Slovakia

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites